Skip to main content

Table 4 Cohort study: preadmission statin use and prognosis within 30 days following hospitalization for pneumonia in Denmark (1997-2009)

From: The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study

Statin use

Pneumonia patients

(n = 70,953)

Number of deaths

30-day mortality, percentage

Crude HR

(95% CI)

Adjusteda HR

(95% CI)

Never

61,827

9,282

15.1

1.00 (reference)

1.00 (reference)

Former (>125 days)

1,903

272

14.3

0.95 (0.84-1.07)

0.91 (0.80-1.03)

Current (≤125 days)

7,223

813

11.3

0.74 (0.69-0.79)

0.73 (0.67-0.79)

Current (≤125 days) supplementary adjusted model for 2001-2009

6,883

788

11.4

0.77 (0.71-0.83)

0.76 (0.70-0.83)

  1. aAdjusted for age, sex, calendar period, marital status, urbanization of place of residence, any recent surgical procedure, 20 different comorbidities, alcoholism-related conditions, and 19 different preadmission medications. The supplementary model for 2001-2009 is also adjusted for receipt of current year's influenza vaccine, dementia, social medicine-related consultations, application for reimbursement for chronic and terminal illness, conversational therapy, and preventive consultations and services. CI, confidence interval; HR, hazard ratio.